1. Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
- Author
-
Zelniker, Thomas A. and Braunwald, Eugene
- Subjects
- *
TYPE 2 diabetes , *CHRONIC kidney failure , *CHRONICALLY ill , *CLINICAL trials , *ATHEROSCLEROSIS complications , *DISEASE progression , *RELATIVE medical risk , *KIDNEYS , *HEART , *HYPOGLYCEMIC agents , *CARDIOVASCULAR diseases , *BLOOD sugar , *TYPE 1 diabetes , *ATHEROSCLEROSIS , *PHARMACODYNAMICS , *DISEASE complications ,CHRONIC kidney failure complications - Abstract
Changes in the regulatory guidelines by the U.S. Food and Drug Administration and the European Medical Agency requiring large-scale trials that study the cardiovascular safety of new glucose-lowering drugs have improved our understanding of type 2 diabetes mellitus. Unexpectedly, these trials demonstrated that sodium-glucose cotransporter 2 inhibitors reduce adverse cardiovascular outcomes. This second part of this 2-part review summarizes the findings of recent clinical trials and their clinical implications and describes ongoing trials and future areas of research. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF